Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 3Inflammation 2Frailty 2Small Cell Lung Carcinoma 1Radiodermatitis 1Prostatic Neoplasms 1Papillomavirus Infections 1Low-Grade Intraepithelial Neoplasia of Cervix 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Esophageal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 112Fluorouracil 104Leucovorin 91Irinotecan 91Capecitabine 59Bevacizumab 58Cetuximab 46Folfox protocol 28Colonoscopy 24Panitumumab 19Chemotherapy, Adjuvant 19Blood Specimen Collection 19Drug Therapy 18Nivolumab 17Magnetic Resonance Spectroscopy 17Radiotherapy 16Exercise 16Early Intervention, Educational 16Surveys and Questionnaires 15Laparoscopy 15Surgical Procedures, Operative 13Floxuridine 13Biopsy 13trifluridine tipiracil drug combination 12pembrolizumab 12XELOX 12Neoadjuvant Therapy 11Methods 11Immunohistochemistry 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colonic Neoplasms × epigallocatechin gallate × Clear all
NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡